期刊文献+

根治性前列腺切除术在盆腔淋巴结受侵及转移性前列腺癌中的应用及现状 被引量:3

Application and present situation of radical prostatectomy in patients with pelvic lymph node positive disease and metastatic prostate cancer
原文传递
导出
摘要 前列腺癌为临床常见泌尿系肿瘤,该疾病具有很高的侵袭性,大多数前列腺癌患者在初诊时已经出现转移。传统观念认为盆腔淋巴结受侵及转移性前列腺癌患者应当选择全身系统性治疗,不推荐根治性前列腺切术。近年来,随着技术手段的进步,经过筛选,一些患者接受了根治手术并达到了良好的生存获益效果。根治性前列腺切术应用于盆腔淋巴结受侵及转移性前列腺癌这一新的理念逐渐被临床医师所重视。为此,本文对根治性前列腺切除术在盆腔淋巴结受侵及转移性前列腺癌中的应用及现状作一综述。 Prostate cancer is a common urinary system disease and a very aggressive malignancy.Most patients are presented with metastasis at diagnosis.Traditionally,systematic treatment was recommended in patients with pelvic lymph node positive disease and metastatic prostate cancer.Radical prostatectomy was discouraging.In recent years,with the development of treatment method,some cases underwent radical prostatectomy and achieved positive outcomes.Radical prostatectomy used in patients with pelvic lymph node positive disease and metastatic prostate cancer,a new concept,is gaining more and more attention.Thus,the purpose of this review was to summarize the current knowledge on radical prostatectomy in this setting.
作者 赵炎 梁杰 林英立 戚景光 杨宁 ZHAO Yan;LIANG Jie;LIN Yingli;QI Jingguang;YANG Ning(Department of Urology,Xuzhou Cancer Hospital,Affiliated Hospital of Jiangsu University,Xuzhou,Jiangsu,221005,China)
出处 《临床泌尿外科杂志》 2019年第12期1009-1012,共4页 Journal of Clinical Urology
关键词 根治性前列腺切除术 前列腺癌 转移性 盆腔淋巴结受侵 radical prostatectomy prostate cancer metastatic pelvic lymph node positive
  • 相关文献

参考文献3

二级参考文献48

  • 1Center M M,Jemal A,Lortet-Tieulent J,et al.International variation in prostate cancer incidence and mortality rates[J].Eur Urol,2012,61(6):1079-1092.
  • 2Chen W,Zheng R,Baade P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin 2016,66(2):115-132.
  • 3Lassi K,Dawson N A.Emerging therapies in castrateresistant prostate cancer[J].Curr Opin Oncol,2009,21(3):260-265.
  • 4Cookson M S,Roth B J,Dahm P,et al.Castration-resistant prostate cancer:AUA Guideline[J].J Urol,2013,190(2):429-438.
  • 5Berthold D R,Pond G R,Soban F,et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer:updated survival in the TAX327study[J].J Clin Oncol,2008,26(2):242-245.
  • 6Petrylak D P,Tangen C M,Hussain M H,et al.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer[J].N Engl J Med,2004,351(15):1513-20.
  • 7James N D,Sydes M R,Clarke N W,et al.Addition of docetaxel,zoledronic acid,or both to first-line longterm hormone therapy in prostate cancer(STAM-PEDE):survival results from an adaptive,multiarm,multistage,platform randomised controlled trial[J].Lancet,387(10024):1163-1177.
  • 8De Bono J S,Oudard S,Ozguroglu M,et al.Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:a randomised open-label trial[J].Lancet,376(9747):1147-1154.
  • 9Shigeta K,Miura Y,Naito Y,et al.Cabazitaxel for castration-resistant prostate cancer[J].Lancet,2011,377(9760):121.
  • 10Mita A C,Denis L J,Rowinsky E K,et al.Phase Iand pharmacokinetic study of XRP6258(RPR116258A),a novel taxane,administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors[J].Clin Cancer Res,2009,15(2):723-730.

共引文献15

同被引文献23

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部